GSK plc (LSE/NYSE: GSK) has announced new findings from the AReSVi-006 Phase III trial, which assessed the effectiveness of a single dose of Arexvy, a recombinant adjuvanted vaccine for respiratory…
Veterinary technicians play a vital role in the veterinary field, carrying out important tasks such as assisting in surgeries, conducting diagnostic tests, and providing emergency care. To meet the increasing…
Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor,…
Gilead Sciences, Inc. has announced the presentation of new findings from its antiviral research and development programs at IDWeek 2024, scheduled for October 16-19. The presentations will include data from…
Pfizer Inc. (NYSE: PFE) has announced encouraging topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study, evaluating TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)…
Pfizer Inc. (NYSE: PFE) has announced that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in adults…
AstraZeneca’s Airsupra (albuterol/budesonide) has demonstrated promising outcomes in the BATURA Phase IIIb trial, achieving its primary endpoint by significantly and meaningfully reducing the risk of severe asthma exacerbations when used…
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented promising two-year findings from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, held from October 8-12, 2024. The study…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Itovebi™ (inavolisib) for use in combination with palbociclib (Ibrance®) and fulvestrant to treat…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced plans to present new research at IDWeek 2024 in Los Angeles, CA, from October 16-19. The company…
Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, announced today that its Phase 3 KEYNOTE-689 trial met the primary endpoint of event-free survival (EFS) for KEYTRUDA®…
SSegal Trials is proud to have played a significant role in the FDA approval of COBENFY™ (xanomeline and trospium chloride), a pioneering first-in-class muscarinic agonist developed by Bristol Myers Squibb…